Q3 Financial Results 2024-25

Beximco Pharmaceuticals PLC

24 June 2026

 

24 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Q3 Financial Results 2024-25

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the third quarter and nine months ended 31 March 2025.

Financial Highlights (Consolidated)

Nine months ended 31 March 2025

·      Net revenue increased 10.8% to Bangladesh Taka ("BDT") 36,622.0m / £235.0m (2023-24: BDT 33,050.9m / £239.1m)

o  Domestic sales increased 8.5% to BDT 33,617.7m / £215.7m (2023-24: BDT 30,987.0m / £224.1m)

o  Export sales increased 45.6% to BDT 3,004.3m / £19.3m (2023-24: BDT 2,063.9m / £14.9m)

·      Profit after tax increased 20.3% to BDT 5,261.0m / £33.8m (2023-24: BDT 4,374.7m / £31.6m)

Third-quarter ended 31 March 2025

·      Net revenue increased 14.8% to BDT 12,608.6m / £80.9m (2023-24: BDT 10,987.3m / £79.5m)

·      Profit after tax increased 26.3% to BDT 1,726.0m / £11.1m (2023-24: BDT 1,366.6m / £9.9m)

The detailed accounts can be viewed at the Company website: www.beximcopharma.com

For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.

(Exchange rates of £1=Taka 155.8649 for 31 March 2025 and £1=Taka 138.2585 for 31 March 2024 have been used in this announcement.)

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: [phone], Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: [phone], Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: [phone], Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: [phone] / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: [phone]

FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of financial position (Un-audited)

As at March 31, 2025

	March 31, 2025		Taka '000 June 30, 2024
ASSETS
Non-current assets	49,405,558		48,526,439
Property, plant and equipment	43,383,769		42,487,711
Right-of-use assets	582,493		561,597
Intangible assets	4,691,106		4,720,697
Deferred tax asset	52,646		60,891
Goodwill	674,570		674,570
Other investments	20,974		20,973
Current assets	25,449,285		20,817,584
Inventories	14,100,238		12,118,129
Spares and supplies	844,783		896,665
Trade and other receivables	4,439,493		3,767,319
Loans, advances, deposits and prepayments	2,942,187		2,686,195
Advance income tax	339,484		295,170
Short term investment	900,000		200,000
Cash and cash equivalents	1,883,100		854,106
TOTAL ASSETS	74,854,843		69,344,023
SHAREHOLDERS' EQUITY AND LIABILITIES
Equity attributable to the owners of the company	51,398,004		47,949,965
Share capital	4,461,121		4,461,121
Share premium	5,269,475		5,269,475
Excess of issue price over face value of GDRs	1,689,637		1,689,637
Capital reserve on merger	294,951		294,951
Revaluation surplus	1,134,729		1,137,306
Unrealized gain/(loss)	18,149		18,148
Retained earnings	38,529,942		35,079,327
Non-controlling interest	3,948,520		3,952,938
TOTAL EQUITY	55,346,524		51,902,903
Non-current liabilities	8,389,072		7,879,133
Long term borrowings-net of current maturity	1,963,675		1,757,971
Liability for gratuity, pension and WPPF	3,863,051		3,546,580
Deferred tax liability	2,562,346		2,574,582
Current liabilities	11,119,247		9,561,987
Short term borrowings	4,386,777		2,996,660
Long term borrowings-current maturity	1,091,878		1,270,800
Trade and other payables	3,324,104		3,671,372
Accrued expenses	1,272,457		1,106,665
Dividend payable	311,718		87,223
Income tax payable	732,313		429,267
TOTAL LIABILITIES	19,508,319		17,441,120
TOTAL EQUITY AND LIABILITIES	74,854,843		69,344,023

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income (Un-audited)

For the period July 2024-March 2025

							Taka '000
	July 2024 - March 2025		July 2023 - March 2024		January - March 2025		January - March 2024
Net revenue	36,621,960		33,050,916		12,608,553		10,987,338
Cost of goods sold	(19,822,775)		(18,448,115)		(6,787,928)		(6,184,085)
Gross profit	16,799,185		14,602,801		5,820,625		4,803,253
Operating expenses	(9,288,133)		(8,083,749)		(3,397,217)		(2,826,393)
General and administrative expenses	(1,026,632)		(985,625)		(338,255)		(333,191)
Selling, marketing and distribution expenses	(8,261,501)		(7,098,124)		(3,058,962)		(2,493,202)
Profit from operations	7,511,052		6,519,052		2,423,408		1,976,860
Other income	481,900		246,324		255,345		114,876
Finance cost	(802,608)		(860,732)		(314,630)		(289,030)
Profit before tax and WPPF	7,190,344		5,904,644		2,364,123		1,802,706
Contribution to WPPF	(351,606)		(286,781)		(116,347)		(86,901)
Profit before tax	6,838,738		5,617,863		2,247,776		1,715,805
Income tax expenses	(1,577,731)		(1,243,136)		(521,780)		(349,247)
Current tax	(1,580,974)		(1,293,986)		(517,572)		(369,934)
Deferred tax	3,243		50,850		(4,208)		20,687
Profit after tax	5,261,007		4,374,727		1,725,996		1,366,558
Profit/(loss) attributable to:
Owners of the Company	5,231,738		4,350,901		1,721,356		1,364,518
Non-controlling interest	29,269		23,826		4,640		2,040
	5,261,007		4,374,727		1,725,996		1,366,558
Other comprehensive income/(loss)	1		-		-		-
Total comprehensive income	5,261,008		4,374,727		1,725,996		1,366,558
Total comprehensive income attributable to:
Owners of the Company	5,231,739		4,350,901		1,721,356		1,364,518
Non-controlling interest	29,269		23,826		4,640		2,040
	5,261,008		4,374,727		1,725,996		1,366,558
Earnings per share (EPS)	11.73		9.75		3.86		3.06

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of changes in equity (Un-audited)

For the period July 2024-March 2025

For the period July 2024-March 2025

Taka '000

	Share capital	Share premium	Excess of issue price over Face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2024	4,461,121	5,269,475	1,689,637	294,951	1,137,306	18,148	35,079,327	47,949,965	3,952,938	51,902,903
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	5,231,738	5,231,738	29,269	5,261,007
Other comprehensive income/(loss)	-	-	-	-	-	1	-	1	-	1
Transactions with the shareholders:
Cash dividend	-	-	-	-	-	-	(1,784,448)	(1,784,448)	(33,687)	(1,818,135)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(3,325)	-	3,325	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	748	-	-	748	-	748
Balance as on March 31, 2025	4,461,121	5,269,475	1,689,637	294,951	1,134,729	18,149	38,529,942	51,398,004	3,948,520	55,346,524
Net asset value (NAV) per share							Tk.	115.21

For the period July 2023-March 2024

	Share capital	Share premium	Excess of issue price over Face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2023	4,461,121	5,269,475	1,689,637	294,951	1,141,178	18,148	30,806,194	43,680,704	3,938,962	47,619,666
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	4,350,901	4,350,901	23,826	4,374,727
Transactions with the shareholders:
Cash dividend	-	-	-	-	-	-	(1,561,392)	(1,561,392)	(23,267)	(1,584,659)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(3,747)	-	3,747	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	843	-	-	843	-	843
Balance as on March 31, 2024	4,461,121	5,269,475	1,689,637	294,951	1,138,274	18,148	33,599,450	46,471,056	3,939,521	50,410,577
Net asset value (NAV) per share							Tk.	104.17

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of cash flows (Un-audited)

For the period July 2024-March 2025

	July 2024 - March 2025		Taka '000 July 2023 - March 2024
Cash flows from operating activities
Cash receipts from customers and others	36,394,207		33,160,408
Cash paid to suppliers and employees	(30,100,181)		(24,573,460)
Cash generated from operations	6,294,026		8,586,948
Interest paid	(769,431)		(853,639)
Interest received	18,479		2,626
Income tax paid	(1,322,242)		(1,137,217)
Net cash generated from operating activities	4,220,832		6,598,718
Cash flows from investing activities
Acquisition of property, plant and equipment	(2,220,342)		(1,372,788)
Intangible assets	(164,411)		(205,266)
Disposal of property, plant and equipment	40,123		25,252
Dividend received	975		1,143
Short term investment	(700,000)		(200,000)
Net cash used in investing activities	(3,043,655)		(1,751,659)
Cash flows from financing activities
Net increase/(decrease) in long term borrowings	47,161		(910,718)
Net increase/(decrease) in short term borrowings	1,390,117		(2,351,356)
Dividend paid	(1,593,640)		(1,568,205)
Net cash from/(used in) financing activities	(156,362)		(4,830,279)
Increase/(decrease) in cash and cash equivalents	1,020,815		16,780
Opening cash and cash equivalents	854,106		1,135,686
Effect of exchange rate changes on cash and cash equivalents	8,179		7,958
Closing cash and cash equivalents	1,883,100		1,160,424
Net operating cash flows per share	9.46		14.79

 

 

END